Current status of in vivo bioanalysis of nano drug delivery systems

The development of nano drug delivery systems (NDDSs) provides new approaches to fighting against diseases. The NDDSs are specially designed to serve as carriers for the delivery of active pharmaceutical ingredients (APIs) to their target sites, which would certainly extend the benefit of their uniq...

Full description

Bibliographic Details
Main Authors: Tingting Wang, Di Zhang, Dong Sun, Jingkai Gu
Format: Article
Language:English
Published: Elsevier 2020-06-01
Series:Journal of Pharmaceutical Analysis
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2095177919311724
id doaj-a6ed703d467d4c9a8a278e8cdc6c587b
record_format Article
spelling doaj-a6ed703d467d4c9a8a278e8cdc6c587b2021-04-02T13:43:26ZengElsevierJournal of Pharmaceutical Analysis2095-17792020-06-01103221232Current status of in vivo bioanalysis of nano drug delivery systemsTingting Wang0Di Zhang1Dong Sun2Jingkai Gu3Clinical Laboratory, The First Hospital, Jilin University, Changchun, 130061, PR China; Research Center for Drug Metabolism, College of Life Science, Jilin University, Changchun, 130012, PR ChinaResearch Center for Drug Metabolism, College of Life Science, Jilin University, Changchun, 130012, PR ChinaDepartment of Biopharmacy, College of Life Science, Jilin University, Changchun, 130012, PR China; Key Laboratory of Molecular Pharmacology and Drug Evaluation, Ministry of Education, Yantai University, Yantai, 264005, PR China; Corresponding author. Department of Biopharmacy, College of Life Science, Jilin University, Changchun, 130012, PR China.Research Institute of Translational Medicine, The First Hospital, Jilin University, Changchun, 130061, PR China; Research Center for Drug Metabolism, College of Life Science, Jilin University, Changchun, 130012, PR China; Corresponding author. Research Institute of Translational Medicine, the First Hospital, Jilin University, Changchun, 130061, PR China.The development of nano drug delivery systems (NDDSs) provides new approaches to fighting against diseases. The NDDSs are specially designed to serve as carriers for the delivery of active pharmaceutical ingredients (APIs) to their target sites, which would certainly extend the benefit of their unique physicochemical characteristics, such as prolonged circulation time, improved targeting and avoiding of drug-resistance. Despite the remarkable progress achieved over the last three decades, the understanding of the relationships between the in vivo pharmacokinetics of NDDSs and their safety profiles is insufficient. Analysis of NDDSs is far more complicated than the monitoring of small molecular drugs in terms of structure, composition and aggregation state, whereby almost all of the conventional techniques are inadequate for accurate profiling their pharmacokinetic behavior in vivo. Herein, the advanced bioanalysis for tracing the in vivo fate of NDDSs is summarized, including liquid chromatography tandem-mass spectrometry (LC-MS/MS), Förster resonance energy transfer (FRET), aggregation-caused quenching (ACQ) fluorophore, aggregation-induced emission (AIE) fluorophores, enzyme-linked immunosorbent assay (ELISA), magnetic resonance imaging (MRI), radiolabeling, fluorescence spectroscopy, laser ablation inductively coupled plasma MS (LA-ICP-MS), and size-exclusion chromatography (SEC). Based on these technologies, a comprehensive survey of monitoring the dynamic changes of NDDSs in structure, composition and existing form in system (i.e. carrier polymers, released and encapsulated drug) with recent progress is provided. We hope that this review will be helpful in appropriate application methodology for investigating the pharmacokinetics and evaluating the efficacy and safety profiles of NDDSs.http://www.sciencedirect.com/science/article/pii/S2095177919311724NDDSsPolymerMethodologyPharmacokineticsRelease
collection DOAJ
language English
format Article
sources DOAJ
author Tingting Wang
Di Zhang
Dong Sun
Jingkai Gu
spellingShingle Tingting Wang
Di Zhang
Dong Sun
Jingkai Gu
Current status of in vivo bioanalysis of nano drug delivery systems
Journal of Pharmaceutical Analysis
NDDSs
Polymer
Methodology
Pharmacokinetics
Release
author_facet Tingting Wang
Di Zhang
Dong Sun
Jingkai Gu
author_sort Tingting Wang
title Current status of in vivo bioanalysis of nano drug delivery systems
title_short Current status of in vivo bioanalysis of nano drug delivery systems
title_full Current status of in vivo bioanalysis of nano drug delivery systems
title_fullStr Current status of in vivo bioanalysis of nano drug delivery systems
title_full_unstemmed Current status of in vivo bioanalysis of nano drug delivery systems
title_sort current status of in vivo bioanalysis of nano drug delivery systems
publisher Elsevier
series Journal of Pharmaceutical Analysis
issn 2095-1779
publishDate 2020-06-01
description The development of nano drug delivery systems (NDDSs) provides new approaches to fighting against diseases. The NDDSs are specially designed to serve as carriers for the delivery of active pharmaceutical ingredients (APIs) to their target sites, which would certainly extend the benefit of their unique physicochemical characteristics, such as prolonged circulation time, improved targeting and avoiding of drug-resistance. Despite the remarkable progress achieved over the last three decades, the understanding of the relationships between the in vivo pharmacokinetics of NDDSs and their safety profiles is insufficient. Analysis of NDDSs is far more complicated than the monitoring of small molecular drugs in terms of structure, composition and aggregation state, whereby almost all of the conventional techniques are inadequate for accurate profiling their pharmacokinetic behavior in vivo. Herein, the advanced bioanalysis for tracing the in vivo fate of NDDSs is summarized, including liquid chromatography tandem-mass spectrometry (LC-MS/MS), Förster resonance energy transfer (FRET), aggregation-caused quenching (ACQ) fluorophore, aggregation-induced emission (AIE) fluorophores, enzyme-linked immunosorbent assay (ELISA), magnetic resonance imaging (MRI), radiolabeling, fluorescence spectroscopy, laser ablation inductively coupled plasma MS (LA-ICP-MS), and size-exclusion chromatography (SEC). Based on these technologies, a comprehensive survey of monitoring the dynamic changes of NDDSs in structure, composition and existing form in system (i.e. carrier polymers, released and encapsulated drug) with recent progress is provided. We hope that this review will be helpful in appropriate application methodology for investigating the pharmacokinetics and evaluating the efficacy and safety profiles of NDDSs.
topic NDDSs
Polymer
Methodology
Pharmacokinetics
Release
url http://www.sciencedirect.com/science/article/pii/S2095177919311724
work_keys_str_mv AT tingtingwang currentstatusofinvivobioanalysisofnanodrugdeliverysystems
AT dizhang currentstatusofinvivobioanalysisofnanodrugdeliverysystems
AT dongsun currentstatusofinvivobioanalysisofnanodrugdeliverysystems
AT jingkaigu currentstatusofinvivobioanalysisofnanodrugdeliverysystems
_version_ 1721564064580108288